Opportunity Scan

Diamonds in the Rough

Cross-referencing fundamental value against technical exhaustion to isolate beaten-down ARKG constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.

8 in diamond zone29 scored

Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.

Alpha Quadrant — Valuation × Technical Exhaustion

X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.

Accumulation (MFI ≥ 55)Neutral flowDistribution (MFI ≤ 45)Diamond-zone ring

◆ Diamond in the RoughCheap + oversold. Deep value in a technically exhausted state — the prime target.

Fairly Valued WinnerCheap + extended. Strong action backed by earnings, but late for new entries.

Value TrapExpensive + beaten down. Falling yet still richly valued — structurally suspect.

Momentum DarlingExpensive + extended. Crowded leaders with mean-reversion risk.

Diamond Candidates

Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.

#
1	NRIX	Nurix Therapeutics, Inc. Common stock	47.9	14.14%	0.29	58	+6.65%	75	safe
2	SCTX	Scribe Therapeutics Inc. Common Stock	34.0	--	--	34	-41.36%	53	--
3	LLY	Eli Lilly & Co.	31.5	2.85%	0.73	62	+10.10%	67	safe
4	WGS	GeneDx Holdings Corp. Class A Common Stock	30.0	-5.40%	-0.41	31	-33.52%	39	distress
5	ARCT	Arcturus Therapeutics Holdings Inc. Common Stock	30.0	-115.98%	-0.61	35	-29.41%	23	distress
6	BFLY	Butterfly Network, Inc.	28.8	-4.74%	-0.41	36	-25.88%	16	safe
7	GENB	Generate Biomedicines, Inc. Common Stock	28.3	--	--	39	-24.51%	49	--
8	CMPS	COMPASS Pathways Plc American Depository Shares	25.5	-15.59%	-1.68	40	-17.79%	47	distress
9	FRNM	Freenome, Inc. Common stock	24.9	--	--	40	-17.98%	23	--
10	CRSP	CRISPR Therapeutics AG	24.5	-10.54%	-0.23	40	-10.12%	17	safe
11	NTLA	Intellia Therapeutics, Inc	23.5	-28.91%	-0.91	42	-7.58%	50	distress
12	TWST	Twist Bioscience Corporation Common Stock	21.0	-1.58%	-0.46	44	-11.29%	21	safe
13	SDGR	Schrodinger, Inc. Common Stock	20.2	-10.28%	-0.49	45	-17.85%	13	safe
14	KYMR	Kymera Therapeutics, Inc. Common Stock	18.0	-3.85%	-0.50	49	-3.92%	62	safe
15	TEM	Tempus AI, Inc. Class A Common Stock	17.7	-2.16%	-0.29	47	-10.67%	35	safe

Short-Squeeze Watch

Constituents with the highest composite squeeze score — heavy short interest meeting price support.

#
1	PRME	Prime Medicine, Inc. Common Stock	81.3	33.57%	8.45	+18.01%	critical
2	BEAM	Beam Therapeutics Inc. Common Stock	79.4	33.60%	15.30	+0.71%	critical
3	NTLA	Intellia Therapeutics, Inc	77.0	39.21%	9.47	-7.58%	critical
4	CRSP	CRISPR Therapeutics AG	76.6	23.82%	9.58	-10.12%	critical
5	ABSI	Absci Corporation Common Stock	76.5	31.37%	7.52	-3.87%	critical
6	WGS	GeneDx Holdings Corp. Class A Common Stock	72.8	29.95%	5.95	-33.52%	high
7	RXRX	Recursion Pharmaceuticals, Inc. Class A Common Stock	70.2	36.56%	6.13	+1.37%	high
8	SCTX	Scribe Therapeutics Inc. Common Stock	69.9	26.87%	3.58	-41.36%	high
9	KYMR	Kymera Therapeutics, Inc. Common Stock	66.9	14.77%	11.97	-3.92%	high
10	NRIX	Nurix Therapeutics, Inc. Common stock	65.1	17.99%	9.94	+6.65%	high
11	GENB	Generate Biomedicines, Inc. Common Stock	61.5	12.81%	5.75	-24.51%	high
12	ALMR	Alamar Biosciences, Inc. Common Stock	58.9	7.96%	4.25	-4.54%	high

Market cap, valuation, and short-interest metrics are joined to the latest ARKG holdings snapshot; each ticker links to its full quote and analysis page.